Aptamers
targeted mucin - 1 (MUC1), a glycosylated surface protein overexpressed on many cancers, including MCF7 breast cancer cells, and only minimally expressed in MCF - 10A non-cancerous cells.
If confirmed, the findings will open a new line of research that could ultimately lead to significant innovation, as drugs that control amounts of the novel
mucins or that
target specific glycosylating enzymes could lead to a new treatment paradigm for glaucoma.